Butterfield Lisa H
Departments of Medicine, Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh , Pittsburgh, PA , USA.
Front Immunol. 2013 Dec 13;4:454. doi: 10.3389/fimmu.2013.00454.
Dendritic cells (DC) have been tested in cancer immunotherapy clinical trials for two decades. Over this time, the methods of DC culture (or manufacture) have evolved, the approaches for antigen loading have broadened, the maturation signals have varied and different sites of administration have been tested. The post-vaccination immunologic questions asked have also varied between trials and over time. In this review, I will consider multiple aspects of DC-based vaccines tested in cancer patients, including the cell culture, antigen loading, maturation, and delivery, as well as what we have learned from testing immune responses in vaccinated patients who have benefited clinically, and those who have not measurably benefited.
二十年来，树突状细胞（DC）已在癌症免疫治疗临床试验中得到检验。在此期间，DC培养（或制备）方法不断演变，抗原负载方法不断拓展，成熟信号各不相同，且对不同给药部位进行了测试。不同试验以及不同时期所提出的疫苗接种后免疫问题也有所不同。在这篇综述中，我将探讨在癌症患者中测试的基于DC的疫苗的多个方面，包括细胞培养、抗原负载、成熟和递送，以及我们从对临床上受益和未获得明显益处的接种患者的免疫反应测试中学到的知识。
